Our Contribution to the SDGs

What are the Sustainable Development Goals?
The United Nations' 17 Sustainable Development Goals (SDGs) set out a vision for ending poverty, hunger, inequality and protecting the planet’s natural resources by 2030. Realising this ambition will require the private sector, governments and civil society to work together and play their part.

How we support the SDGs
We have identified six areas of responsible business that are core to our strategy and where we can have the greatest positive impact on some of society’s most urgent challenges, including those set-out in the SDGs. We report progress on these commitments each year in our annual ESG Performance Report.

Goal 3: Good Health and Wellbeing
As a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together, we can make the most significant contribution to SDG3 focused on health.

Access to healthcare
Our ambition is to positively impact the health of 2.5 billion people by the end of 2030. We will achieve this by developing vaccines and medicines and making them available through responsible pricing, strategic access programmes and partnerships.
In high-income countries, we apply a value-based approach to balance reward for innovation with affordability. In lower income countries, we use innovative pricing structures as part of our access strategies to extend product reach, including tiered pricing for vaccine tenders based on World Bank income classification.
Our access strategy is guided by our robust and evidence-based processes which prioritise high impact on local needs, insights and experience. As well as this we aim to ensure sustainability through innovative partnerships and local capacity building.

In recognition of the action we are taking to get ahead of disease together, in 2022, we ranked first in the Access to Medicines Index for the eighth consecutive time.

Global health and health security
One of the biggest impacts that we can have is to successfully research and develop innovative, differentiated and high quality medicines and vaccines to improve health.
We also have a responsibility to impact global health, particularly in the prevention and treatment of infectious diseases. We have the largest global health R&D pipeline in the industry, supporting global efforts to reduce the burden of malaria, TB, neglected tropical diseases (NTDs), enteric diseases and the threat of AMR, all which disproportionately affect people in low- and lower middle-income countries.

We have two world-leading, dedicated Global Health innovation hubs for vaccines and medicines that are developing products and technologies to prevent and treat priority infectious diseases. Well-functioning healthcare systems are critical to enabling access to the right treatments and vaccines, so we work together with long-term partners to help strengthen healthcare systems in lower income countries, driven by local needs.

Our contribution to other SDGs

Goal 1: No Poverty
As a global healthcare company, our biggest contribution to support those in vulnerable situations, such as humanitarian disasters, is through medicine and vaccine donations distributed by our partners.

Goal 5: Gender Equality
We are making great headway toward our 2025 aspiration that at least 45% of senior roles are represented by women. In 2022, 42% of senior roles were held by women and 50% of all managers at GSK are women. We also have programmes to recruit and support women at different stages of their careers.

Goal 6: Water and Sanitation
GSK is committed to addressing freshwater challenges as part of our goal to have a net positive impact on nature by 2030. We aim for 100% of our sites to achieve good water stewardship by 2025 and reduce overall water use by 20% by 2030. We are also targeting to be water-neutral in our own operations and with key suppliers in water-stressed regions by 2030.

Goal 8: Decent Work and Economic Growth
Whether in laboratories, manufacturing sites or offices, we want to provide a safe and inclusive workplace for employees and contractors. We have a comprehensive preventive healthcare package for employees and their eligible dependents in every country where we operate.

Find out more here.
Our Contribution to the SDGs continued

Goal 9: Industry, Innovation and Infrastructure
Innovation is at the heart of achieving our purpose. We focus on unlocking the science of the immune system, human genetics and advanced technologies to develop vaccines and specialty medicines to get ahead of disease together.
+ Find out more here.

Goal 10: Reduced Inequalities
We have global disability, gender, ethnicity and LGBT+ councils, chaired by members of the Corporate Executive Committee, which drive our diversity agenda with support from our employee resource groups.
We want GSK to be a workplace where everyone can feel a sense of belonging and can thrive. We are committed to equality of representation so that our leadership reflects our GSK people, and our people reflect the communities we work in.
+ Find out more here.

Goal 12: Responsible Consumption and Production
Our approach to waste and materials is part of our goal to have a net positive impact on nature by 2030. We plan to achieve zero operational waste by 2030 by continuing to reduce the waste from our sites, increasing the amount of materials recovered through circular routes like reuse or recycling as well as eliminating single-use plastics in our operations. We are also aiming for a 10% reduction in waste from our supply chain and to reduce our environmental impact by 25% for our products and packaging by 2030.
+ Find out more here.

Goal 13: Climate Action
We have set a clear pathway to a net zero impact on climate with ambitious goals for 2030 and 2045.
By 2030, we aim to reduce carbon emissions by 80% with the remainder offset through investment in high-quality nature-based solutions, and by 2045, we aim to be at the Science Based Target Initiative Net Zero Standard, with carbon reduced by at least 90% and the remainder tackled through high-quality offsets.
55% of our overall footprint comes from the emissions released when patients using our products, predominantly from the propellant used in metered dose inhalers (MDIs) for asthma and chronic obstructive pulmonary disease. We are investing in an R&D programme to reduce greenhouse gas emissions, with good progress towards reformulating an alternative gas that could reduce the climate impact by up to 90%, if the clinical trials are successful.
+ Find out more here.

Goal 15: Life on Land
Addressing biodiversity is an important part of our goal to have a net positive impact on nature by 2030, and our approach spans both our own sites and our supply chain through the materials we source. To achieve a positive impact on biodiversity at all sites by 2030, we will outweigh any impact we have on local ecosystems by improving habitats, protecting species and improving soil and water quality. As well as this, we aim to have 100% of agricultural, forestry and marine derived materials sustainably sourced and deforestation free by 2030.
+ Find out more here.

Goal 16: Peace, Justice and Strong Institutions
We align our approach on human rights with the UN Guiding Principles on Business and Human Rights. This includes our commitment to respecting the rights contained in the Universal Declaration of Human Rights and the Fundamental Principles and Rights at work set out by the International Labour Organisation.
+ Find out more here.

Goal 17: Partnerships for the Goals
We form diverse partnerships across academia, companies, funders and governments to positively impact health at scale. One example of this is how GSK and Amref Health Africa have partnered for 30 years to help strengthen health systems across Africa. Our programmes in Kenya and Ethiopia that focus on strengthening healthcare systems to reduce the impact of malaria and TB trained over 2,500 healthcare workers in 2022.
+ Find out more here.